Literature DB >> 7532135

Role of nitric oxide in PGF2 alpha-induced ocular hyperemia.

M Astin1, J Stjernschantz, G Selén.   

Abstract

The effect of nitric oxide synthase inhibition on prostaglandin F2 alpha (PGF2 alpha)-induced ocular hyperemia in the rabbit has been studied. PGF2 alpha was administered topically as the isopropyl ester (PGF2 alpha-IE) unilaterally, with the other eye serving as a control. The regional blood flow in the eye was determined with radioactively-labelled microspheres in conscious animals. Synthesis of nitric oxide (NO) was blocked by L-NMMA (200 mg kg-1 b.w., i.v.). PGF2 alpha-IE induced marked hyperemia of the surface structures of the eye (conjunctiva, eye lids, nictitating membrane, anterior sclera), as well as increased blood flow of the anterior uvea. L-NMMA blocked the hyperemia of the surface structures but not completely the increase in blood flow of the anterior uvea. PhXA41 (13,14-dihydro-17-phenyl-18,19,20-trinor-PGF2 alpha-isopropyl ester), a selective prostaglandin FP-receptor agonist, had no significant effect on the ocular blood flow. These results indicate that PGF2 alpha causes surface hyperemia of the eye by activating nitric oxide synthase, but this mechanism seems to be only partly involved in the increase in blood flow of the ciliary processes and the iris. The PGF2 alpha-induced ocular hyperemia is unlikely to be mediated by FP receptors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7532135     DOI: 10.1006/exer.1994.1124

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  11 in total

1.  Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients.

Authors:  M Figus; M Nardi; P Piaggi; M Sartini; G Guidi; L Martini; S Lazzeri
Journal:  Eye (Lond)       Date:  2014-01-17       Impact factor: 3.775

2.  In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in guinea pigs following treatment with bimatoprost ophthalmic solutions 0.01% and 0.03%.

Authors:  Abayomi B Ogundele; David Earnest; Marsha A McLaughlin
Journal:  Clin Ophthalmol       Date:  2010-07-30

3.  A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprost.

Authors:  E Randy Craven; Ching-Chi Liu; Amy Batoosingh; Rhett M Schiffman; Scott M Whitcup
Journal:  Clin Ophthalmol       Date:  2010-12-06

4.  Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy.

Authors:  J Charles Henry; James H Peace; Jeanette A Stewart; William C Stewart
Journal:  Clin Ophthalmol       Date:  2008-09

5.  Cyclooxygenase-2 and its regulation in inflammation.

Authors:  Y S Bakhle; R M Botting
Journal:  Mediators Inflamm       Date:  1996       Impact factor: 4.711

6.  An observational study of bimatoprost 0.01% in patients on prior intraocular pressure-lowering therapy: the Canadian Lumigan(®) RC Early Analysis Review (CLEAR) trial.

Authors:  Andrew C Crichton; Donald R Nixon; Susan Simonyi; Meetu Bhogal; Christopher S Sigouin; Marino J Discepola; Cindy Ml Hutnik; Darryl C Baptiste; David B Yan
Journal:  Clin Ophthalmol       Date:  2014-05-23

Review 7.  Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution.

Authors:  Daniel Lee; Anand V Mantravadi; Jonathan S Myers
Journal:  Clin Ophthalmol       Date:  2017-07-10

8.  An observational study of bimatoprost 0.01% in treatment-naïve patients with primary open angle glaucoma or ocular hypertension: the CLEAR trial.

Authors:  Donald R Nixon; Susan Simonyi; Meetu Bhogal; Christopher S Sigouin; Andrew C Crichton; Marino Discepola; Cindy Ml Hutnik; David B Yan
Journal:  Clin Ophthalmol       Date:  2012-12-18

Review 9.  Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure.

Authors:  Luciano Quaranta; Ivano Riva; Andreas Katsanos; Irene Floriani; Marco Centofanti; Anastasios G P Konstas
Journal:  Clin Ophthalmol       Date:  2015-04-10

10.  Reliable intraocular pressure measurement using automated radio-wave telemetry.

Authors:  Eleftherios I Paschalis; Fabiano Cade; Samir Melki; Louis R Pasquale; Claes H Dohlman; Joseph B Ciolino
Journal:  Clin Ophthalmol       Date:  2014-01-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.